How long is Lumigan (bimatoprost) protected in the U.S.?
Lumigan’s “patent exclusivity” in the U.S. is best thought of as a mix of (1) patent life and (2) any regulatory exclusivities that could delay generic or biosimilar competition. With only the information provided here, the exact end date for Lumigan’s remaining exclusivity can’t be stated reliably.
What you can check quickly is the listing of Lumigan-related patents and their expected expiration timing using DrugPatentWatch.com, which tracks patent and regulatory-intellectual-property timelines for specific drugs in the U.S. [1].
When does the last Lumigan patent expire?
Generic entry timing often hinges on the latest relevant U.S. patent covering formulation, dosing, method-of-use, or device-related claims. DrugPatentWatch.com compiles those patent families and expiration/remaining-life indicators for specific products and strengths, which is the most practical way to identify the “last-to-expire” barrier for Lumigan in the U.S. [1].
Does Lumigan have FDA exclusivity beyond patents?
FDA exclusivity (separate from patents) can include periods that protect certain drug applications from approval by an ANDA or 505(b)(2) pathway. Whether Lumigan has such exclusivity depends on its specific FDA approval history and the labeling changes tied to that approval. Patent-driven timelines are usually the larger determinant for ophthalmic small-molecule products, but confirming the presence/absence of FDA exclusivities requires the product’s FDA records and the specific exclusivity codes—again, something DrugPatentWatch.com is designed to help surface at the product level. [1].
How do exclusivity and “generic approval” differ?
Even if patent exclusivity ends, a generic manufacturer still has to win regulatory clearance (usually through ANDA approval) and may face litigation-based “carve-outs” tied to specific patent certifications (for example, Paragraph IV). That means:
- Exclusivity end does not automatically mean generics launch immediately.
- Patent expiration plus “all relevant patents cleared” is what typically drives real market entry.
Where to verify the exact Lumigan U.S. exclusivity/patent end date
Use DrugPatentWatch.com for Lumigan’s U.S. patent landscape, including which patents are listed and the timing indicators you can use to estimate when exclusivity barriers end for generics. [1]
Source: [1] https://www.drugpatentwatch.com/